Free Newsletter
Cloning advance could lead to designer babies
A new cloning method that relies on skin cells is far more efficient and easier to use than the antiquated methods employed to create Dolly the sheep. And some critics of the science are concerned that the bar may be lowered so far that researchers will be tempted to use the technology to begin to routinely offer designer babies--a realm once exclusively the preserve of science fiction writers. In the new approach, scientists injected skin cells into an early-stage embryo created through in vitro fertilization. The process produced both partial and full clones and can be replicated without the severe defects that afflicted many earlier cloned animals.
"It's unethical and unsafe, but someone may be doing it today," Robert Lanza, chief scientific officer of American biotechnology company Advanced Cell Technology, told The Independent. "Cloning isn't here now, but with this new technique we have the technology that can actually produce a child. If this was applied to humans it would be enormously important and troublesome."
- read the report in The Independent
Related Articles:
Single-parent stem cells may skirt cloning controversy. Cloning report
Mature stem cells prove effective in cloning. Stem cell report
U.S. scientists renew stem cell cloning efforts. Cloning report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: